Is Krystal Biotech, Inc. (KRYS) a Buy, Sell, or Hold?
NASDAQ : KRYS
Krystal Biotech, Inc. — Institutional Ownership
$335.19 USD
$7.69 (2.35%)
- Volume
- 520.34K
- Average Volume
- 408.46K
- Market Capitalization
- $9.88B
- P/E Ratio
- 43.25
- Dividend Yield
- 0.00%
- Price Target
- $327.00
- Year High
- $382.54
- Year Low
- $130.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.46
Institutional Ownership Summary
Institutional Ownership %
1.03%
Investors Holding
73
change: -307 | last: 380
Increased Positions
46
change: -169 | last: 215
Reduced Positions
16
change: -89 | last: 105
New Positions
20
change: -55 | last: 75
Sold Positions
317
change: 274 | last: 43
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: -38.02 | last: 0.3802
Total Invested
111.81M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-04 | Krish S. Krishnan | 3.39M | 11.50% |
| 2026-05-04 | Suma M. Krishnan | 3.39M | 11.50% |
| 2026-04-29 | Vanguard Portfolio Management | 1.48M | 5.05% |
| 2026-03-27 | The Vanguard Group | - | 0.00% |
| 2025-02-05 | STATE STREET CORPORATION | 1.28M | 4.40% |
| 2024-10-16 | STATE STREET CORPORATION | 1.45M | 5.10% |
| 2024-02-13 | The Vanguard Group - 23-1945930 | 2.44M | 8.64% |
| 2023-02-14 | Avoro Capital Advisors LLC | 1.41M | 5.50% |
| 2023-02-14 | Behzad Aghazadeh | 1.41M | 5.50% |
| 2022-02-14 | Steven A. Cohen | 1.86M | 4.00% |
| 2022-02-14 | Point72 Asset Management, L.P. | 1.86M | 4.00% |
| 2022-02-14 | Point72 Capital Advisors, Inc. | 1.86M | 4.00% |
| 2022-02-14 | Cubist Systematic Strategies, LLC | 4514.0 | 4.00% |
| 2022-02-03 | (1) BlackRock, Inc. | 1.61M | 6.40% |
| 2021-12-06 | Point72 Asset Management, L.P. | 1.34M | 4.00% |
| 2021-12-06 | Point72 Capital Advisors, Inc. | 1.34M | 4.00% |
| 2021-12-06 | Cubist Systematic Strategies, LLC | 1042.0 | 4.00% |
| 2021-12-06 | Steven A. Cohen | 1.34M | 4.00% |
| 2021-03-09 | Sun Pharmaceutical Industries Limited | 914.11K | 4.10% |
| 2021-03-09 | Sun Pharma (Netherlands) B.V. | 914.11K | 4.10% |
| 2021-03-09 | Dilip S. Shanghvi | 914.11K | 4.10% |
| 2021-02-16 | Baker Bros. Advisors (GP) LLC | 698.87K | 3.50% |
| 2021-02-16 | Baker Bros. Advisors LP | 698.87K | 3.50% |
| 2021-02-16 | Felix J. Baker | 698.87K | 3.50% |
| 2021-02-16 | Redmile Group, LLC | 1.68M | 8.50% |
| 2021-02-16 | 52-0556948 | 912.0 | 0.00% |
| 2021-02-16 | Julian C. Baker | 698.87K | 3.50% |
| 2021-02-16 | Jeremy C. Green | 1.68M | 8.50% |
| 2021-02-04 | James Topper | 895K | 4.50% |
| 2021-02-04 | FHMLS IX, L.P. | 895K | 4.50% |
| 2021-02-04 | Frazier Life Sciences IX, L.P. | 895K | 4.50% |
| 2021-02-04 | Patrick Heron | 895K | 4.50% |
| 2021-02-04 | FHMLS IX, L.L.C. | 895K | 4.50% |
| 2021-02-02 | (1) BlackRock, Inc. | 1.41M | 7.10% |
| 2020-02-14 | Advisors LLC | 61300.0 | 0.35% |
| 2020-02-14 | OrbiMed Capital LLC | 933.51K | 5.39% |
| 2020-02-14 | Redmile Group, LLC | 1.09M | 6.30% |
| 2020-02-14 | OrbiMed Capital LLC | 933.51K | 5.39% |
| 2020-02-14 | Jeremy C. Green | 1.09M | 6.30% |
| 2020-02-14 | Advisors LLC | 61300.0 | 0.35% |
| 2020-02-14 | 52-0556948 | 1.05M | 6.00% |
| 2020-02-14 | 12.1%(2) | 2.1M | 12.10% |
| 2020-02-13 | 5.2% (2) | 895K | 5.20% |
| 2020-02-13 | 5.2% (2) | 895K | 5.20% |
| 2020-02-13 | 5.2% (2) | 895K | 5.20% |
| 2020-02-13 | 5.2% (2) | 895K | 5.20% |
| 2020-02-13 | 5.2% (2) | 895K | 5.20% |
| 2020-02-07 | Select Biotechnology Portfolio | 1.15M | 6.63% |
| 2020-02-07 | FMR LLC | 1.15M | 6.63% |
| 2020-02-07 | Abigail P. Johnson | 1.15M | 6.63% |
| 2019-02-19 | Krish S. Krishnan | 2.15M | 14.90% |
| 2019-02-19 | Suma M. Krishnan | 2.11M | 14.60% |
| 2019-02-13 | Baker Bros. Advisors (GP) LLC | 784.67K | 5.40% |
| 2019-02-13 | Baker Bros. Advisors LP | 784.67K | 5.40% |
| 2019-02-13 | Julian C. Baker | 784.67K | 5.40% |
| 2019-02-13 | Felix J. Baker | 784.67K | 5.40% |
| 2018-08-27 | 5.7% (2) | 625K | 5.70% |
| 2018-08-27 | 5.7% (2) | 625K | 5.70% |
| 2018-08-27 | 5.7% (2) | 625K | 5.70% |
| 2018-08-27 | 5.7% (2) | 625K | 5.70% |
| 2018-08-27 | 5.7% (2) | 625K | 5.70% |
| 2018-04-04 | Suma M. Krishnan | 2.05M | 19.90% |
| 2018-04-04 | 19.9% (2) | 2.05M | 19.90% |
| 2018-02-14 | RA Capital Management, LLC | 700K | 6.80% |
| 2018-02-14 | Dilip S. Shanghvi | 914.11K | 8.90% |
| 2018-02-14 | Sun Pharmaceutical Industries Limited | 914.11K | 8.90% |
| 2018-02-14 | Sun Pharma (Netherlands) B.V. | 914.11K | 8.90% |
| 2018-02-14 | Peter Kolchinsky | 700K | 6.80% |
KRYS Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $246.54 | 28.94M | $7.14B | $496.3M | $9.34M | $6.65B |
| 2024-12-31 | $156.66 | 28.59M | $4.48B | $344.86M | $7.26M | $4.14B |
| 2023-12-31 | $124.06 | 27.15M | $3.37B | $358.33M | $8.09M | $3.02B |
| 2022-12-31 | $79.22 | 25.49M | $2.02B | $161.9M | $8.93M | $1.87B |
| 2021-12-31 | $69.95 | 22.2M | $1.55B | $341.25M | $8.02M | $1.22B |
| 2020-12-31 | $60.00 | 18.79M | $1.13B | $268.27M | $11.55M | $870.51M |
| 2019-12-31 | $55.38 | 15.9M | $880.6M | $187.51M | $3.26M | $696.35M |
| 2018-12-31 | $20.78 | 11.2M | $232.8M | $103.67M | -$ | $129.13M |
| 2017-12-31 | $10.52 | 5.36M | $56.39M | $49.59M | -$ | $6.8M |
| 2016-12-31 | $10.64 | 4.28M | $45.49M | $1.92M | $1.84M | $45.41M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $258.32 | 29.29M | $7.57B | $501.31M | $9.11M | $7.07B |
| 2025-12-31 | $246.54 | 28.94M | $7.14B | $496.3M | $9.34M | $6.65B |
| 2025-09-30 | $176.53 | 28.95M | $5.11B | $392.6M | $9.51M | $4.73B |
| 2025-06-30 | $137.46 | 28.91M | $3.97B | $353.83M | $9.68M | $3.63B |
| 2025-03-31 | $180.30 | 28.82M | $5.2B | $308.77M | $9.66M | $4.9B |
| 2024-12-31 | $156.66 | 28.76M | $4.5B | $344.86M | $7.26M | $4.17B |
| 2024-09-30 | $182.03 | 28.72M | $5.23B | $373.97M | $7.48M | $4.86B |
| 2024-06-30 | $182.27 | 28.6M | $5.21B | $345.79M | $7.69M | $4.87B |
| 2024-03-31 | $176.07 | 28.3M | $4.98B | $359.01M | $7.9M | $4.63B |
| 2023-12-31 | $124.06 | 28.17M | $3.49B | $358.33M | $8.09M | $3.14B |
| 2023-09-30 | $116.00 | 28.04M | $3.25B | $373.24M | $8.32M | $2.89B |
| 2023-06-30 | $117.40 | 26.66M | $3.13B | $275.88M | $8.54M | $2.86B |